Semaglutide Trial Investigates Improved Embryo Quality for Overweight IVF Patients

Infertility affects millions globally, with obesity being a significant contributing factor, often leading to poorer outcomes in in vitro fertilization (IVF). Overweight and obese women undergoing IVF frequently experience reduced embryo quality and lower pregnancy rates. While Semaglutide, a GLP-1 receptor agonist, is known for its efficacy in weight management and improving metabolic health, its direct impact on reproductive outcomes, specifically whether a pre-treatment with semaglutide can enhance embryo quality in this population, remains underexplored.

As an ongoing randomized controlled trial (NCT07242534) with an estimated completion in May 2027, specific results are not yet available. However, the study's primary objective is to determine if Semaglutide pre-treatment significantly increases the number of good-quality blastocysts in overweight and obese women undergoing IVF. The researchers hypothesize a superior outcome in the intervention group, suggesting a potential for improved embryo development. The single most important finding, once available, will be the quantitative difference in the number of good-quality blastocysts obtained between the Semaglutide pre-treatment group and the control group, indicating the efficacy of the intervention. Secondary outcomes will include changes in BMI, weight loss, and ovarian stimulation parameters such as oocyte yield and maturation rates, providing a comprehensive view of Semaglutide's impact on fertility.